<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[Progress in Biochemistry and Biophysics -->Special Topic: Depression Research]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Progress on The Relationship Between Microglia Polarization and Depression]]></title>
<link><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20210199]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Microglia mainly control the immune efficiency of the central nervous system and play an important role in various psychiatric diseases. Neuroinflammation triggered by the signaling pathway activation is related to the development of depression. Microglia are the main mediators of neuroinflammation. Different stimulations promote the polarization of microglia, which secrete inflammatory cytokines that affect the regulation of neuroinflammation. Clinical and experimental research <i>in vivo</i> and<i> in vitro </i>have demonstrated the relationship of depression with neuroinflammation mediated by microglial polarization. The possible mechanisms of polarization mediating depression involve NF-κB signaling pathway activation, respiratory bursts, complement receptor 3 (CR3) signaling pathway activation, NLRP3 inflammation activation, cannibalism receptor 1 (CB1) activation, Notch-1 signal pathway stimulation, and PPARγ receptor activation. This review discusses research progress on the relationship between microglial polarization and depression.]]></description>
<pubDate>2021/12/23 13:40:43</pubDate>
<category><![CDATA[Special Topic: Depression Research]]></category>
<author><![CDATA[WAN Teng,GAO Xue,LIU Shun-Feng,MENG An-Na,Lü Hong-Ying,WU Zhuan and ZHOU Shou-Hong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WAN Teng,GAO Xue,LIU Shun-Feng,MENG An-Na,Lü Hong-Ying,WU Zhuan and ZHOU Shou-Hong</atom:name>
</atom:author>
<guid><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20210199]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Progress of CREB-regulated Transcription Coactivator 1 in Depression]]></title>
<link><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20210214]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Depression is one of the world’s serious health problems with high prevalence, high disability and high recurrence rate, and places a great burden on society. The newly discovered CREB-regulated transcription coactivator 1 (CRTC1) is highly expressed in the brain, especially in hippocampal neurons, and plays an important role in dendrite growth, long-term synaptic plasticity and behavior. Since <i>Crtc1</i> knockout (<i>Crtc1<sup>-/-</sup></i>) mice were first successfully prepared in 2012 and <i>Crtc1<sup>-/-</sup></i> mice exhibited a depression-like behavioral phenotype, the growing clues suggest that CRTC1 is involved in depression. Our previous work demonstrates that knockdown of CRTC1 in hippocampal dentate gyrus directly induced depression-like behavior in mice. Downregulation of CRTC1 expression in hippocampus is associated with depression-like behaviors in CUMS (chronic unpredictabk mild stress), CSDS (chronic social defeat stress) and CRS (chronic restrain stress) mouse models, LPS(lipopolysaccharide)-treated mouse model and prenatal stress-induced depression model in offspring rats. Furthermore, abnormal CRTC1 expression or activation may be involved in depression-like behavior <i>via</i> SIK2/CRTC1/CREB/BDNF pathway, CRTC1/BDNF/TrkB/VGF pathway, agmatinergic system and neuroinflammation. In addition, <i>Crtc1<sup>-/-</sup></i> mice are shown to be resistant to the antidepressant effects of the tricyclic antidepressants such as fluoxetine, desipramine, venlafaxine and imipramine <i>etc.</i>, suggesting that CRTC1 alterations may be related with treatment-resistant depression. Histone deacetylase (HDAC) inhibitor suberoylanilide hydroxamic acid (SAHA) partially rescues the depression-like behavior of <i>Crtc1<sup>-/-</sup></i> mice accompanied by an increased expression of BDNF, the effects are mediated by CRTC1. Although CRTC1 expression is disturbed in the brain of depression-related models, whether and how it is involved in the process of neurogenesis and neuroplasticity impairments in depression still needs further research. This article reviews the research of CRTC1 in depression from the aspects of behavior, related signal pathways and participation in the role of antidepressants.]]></description>
<pubDate>2021/12/23 13:40:43</pubDate>
<category><![CDATA[Special Topic: Depression Research]]></category>
<author><![CDATA[LI De-Zhu,NI Sai-Qi,ZHANG Min-Jian,LU Si-Yi,LIU Xin-Lan and ZHANG Jun-Fang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LI De-Zhu,NI Sai-Qi,ZHANG Min-Jian,LU Si-Yi,LIU Xin-Lan and ZHANG Jun-Fang</atom:name>
</atom:author>
<guid><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20210214]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research Progress on The Effects of Phototherapy and Light Dose on Depression]]></title>
<link><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20210198]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Depression is a kind of mental disorder with high prevalence rate, easy relapse and high suicide rate, which can easily lead to cognitive impairment and other problems. Phototherapy, with its advantages of noninvasive, less side effects and quick curative effect, has attracted wide attention, which provides a new possibility for regulating the biorhythm and sleep disorders of depression. Light signals are projected through retinal ganglion cells to depressed brain areas to participate in non-visual imaging functions, activating nerve cell activity, secreting neurotransmitters to induce physiological changes in neural pathways, and regulating circadian rhythms, mood, and sleep in the biological organism to improve depressive behavior. The most common forms of light therapy include bright light therapy, blue light therapy and near infrared light therapy. The choice and use of different light sources can have different effects on the therapeutic outcome, and their wavelength, dose and optimal mode of action are closely related to the therapeutic outcome. The results also suggest that the use of low intensity beneficial wavelengths of blue light can have the same antidepressant effect as high intensity bright light therapy, but the best mode of application of phototherapy is still controversial. In order to promote the application of phototherapy in the field of life science and clinical practice, a large number of studies on optical parameters in clinical and animal models are still needed. This paper will summarize the current therapeutic targets of light therapy in depression-related brain regions and downstream neural circuits, explore the mechanisms of action of different spectra and their therapeutic parameters, discover the advantages of their light sources and suitable therapeutic parameters, and propose the problems of phototherapy, such as the optimal light parameters, the universality of different populations, and the safety issues arising from unsuitable light sources, which are still to be solved. As phototherapy continues to be explored in depth, the selection of optimal phototherapy pathways, the screening of optimal light parameters, and the combination of other classical therapeutic methods will provide references for experimental studies and clinical applications of phototherapy against depression and produce breakthroughs in the treatment of depression.]]></description>
<pubDate>2021/12/23 13:40:45</pubDate>
<category><![CDATA[Special Topic: Depression Research]]></category>
<author><![CDATA[CHEN Hong-Li,GAO Jing-Jing,YANG Jia-Jia,JIANG Zhong-Di,CHEN Rui-Juan,LIU Shuang and MING Dong]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CHEN Hong-Li,GAO Jing-Jing,YANG Jia-Jia,JIANG Zhong-Di,CHEN Rui-Juan,LIU Shuang and MING Dong</atom:name>
</atom:author>
<guid><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20210198]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Therapeutic and Neural Mechanisms of Light Therapy for Depression]]></title>
<link><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20210210]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Depression is a significant and persistent mood or low state of mind as the main performance of mental illness. Light therapy has attracted more and more attention due to its low side effects and low cost. Light therapy is a physical therapy method that uses artificial or natural light to prevent and cure diseases by using light of different duration and intensity. Animal and clinical trials have shown that light therapy can effectively relieve depressive symptoms. However, the neural mechanism of the antidepressant effect of light therapy is still not fully understood, and the application paradigm of light therapy is still controversial. This paper briefly introduces the clinical application light therapy in the seasonal depressive disorder (SDD), bipolar disorder (BD), sub-threshold depression (SD), major depressive disorder (MDD), perinatal depression (PPD), post stroke depression (PSD), and the underlying mechanisms of those effects of light therapy in anti-depression. Animal studies reveal that the effects of light on mood <i>via</i> intrinsically photosensitive retinal ganglion cells to perihabenular nucleus (ipRGC-PHb) pathway. A recent report demonstrated that activation of the disynaptic retina-vLGN/IGL-LHb pathway underlies the anti-depressive effects of light therapy. Monoamine neurotransmitter as well as cortisol are also involved in regulating depressive-like behaviors during light therapy. The current review provides potentially theoretical basis for the optimization and promotion of light therapy in anti-depression.]]></description>
<pubDate>2021/12/23 13:40:46</pubDate>
<category><![CDATA[Special Topic: Depression Research]]></category>
<author><![CDATA[CUI Ke-Ke,JIN Lei,JIN Bin-Jie,WANG Zhi-Kai,WANG Xiang-Qun,ZOU Dan-Dan and WANG Zheng-Chun]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CUI Ke-Ke,JIN Lei,JIN Bin-Jie,WANG Zhi-Kai,WANG Xiang-Qun,ZOU Dan-Dan and WANG Zheng-Chun</atom:name>
</atom:author>
<guid><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20210210]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Calcium Homeostasis Modulator 2 Q87A Mutation Promotes Depression Susceptibility]]></title>
<link><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20210048]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Calcium homeostasis modulator 2 (Calhm2) is involved in the modulation of Ca<sup>2+</sup> activity and ATP release. Our previous work has demonstrated that Calhm2 plays a crucial role in the progression of depression by regulating the astrocytic ATP release. In order to further explore the role and mechanism of Calhm2 in the development of depression, we firstly predicted the ATP binding site (glutamine, amino acid 87) of Calhm2, and established a mouse line that carried calhm2 mutation by mutating the glutamine to alanine (Q87A). Secondly, by using the primary culture of astrocyte and ATP detection analysis, we found that Calhm2 Q87A mutation resulted in a significant decrease of ATP release in astrocytes. Furthermore, we found that the ATP release decreased in hippocampal slice from Calhm2 Q87A mutated mice. Importantly, Calhm2 Q87A mutated mice showed a higher susceptibility to develop depression-like symptoms than that of wild type mice when exposed to chronic unpredictable mild stress (CUMS). Taken together, we identified that Q87 site is important for Calhm2-mediated ATP release in astrocytes and this point mutation of Calhm2 promotes depression susceptibility induced by stress in mice. The present work further defines the molecular mechanism of Calhm2 in the development of depression, with the implication of a potential avenues for the diagnosis and therapeutics of depression-related diseases.]]></description>
<pubDate>2021/12/23 13:40:49</pubDate>
<category><![CDATA[Special Topic: Depression Research]]></category>
<author><![CDATA[LIAO Yang,PAN Rui-Yuan and YUAN Zeng-Qiang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIAO Yang,PAN Rui-Yuan and YUAN Zeng-Qiang</atom:name>
</atom:author>
<guid><![CDATA[http://www.pibb.ac.cn/pibben/article/abstract/20210048]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>